NCT03336619已完成3 期
A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1,030
- 试验地点
- 1
- 主要终点
- Time From First Dose to Symptom Response
研究概览
简要总结
Trial to evaluate efficacy and safety of nitazoxanide (NTZ) in the treatment of uncomplicated influenza.
详细描述
A multicenter, randomized, double-blind, placebo controlled trial to evaluate efficacy and safety of nitazoxanide (NTZ) in the treatment of uncomplicated influenza.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female subjects at least 12 years of age
- •Presence of clinical signs and/or symptoms consistent with an acute illness compatible with influenza infection (each of the following is required):
- •oral temperature ≥99.4°F or ≥37.4°C (obtained in office or self- measured within 12 hours prior to screening - if self-measured, subjects must also have taken an antipyretic within 4 hours prior to screening), AND
- •at least one of the following respiratory symptoms (cough, sore throat, nasal obstruction), AND
- •one of the following constitutional symptoms (fatigue, headache, myalgia, feverishness).
- •Confirmation of influenza A or B infection in the local community by one of the following means:
- •the institution's local laboratory,
- •the local public health system,
- •the national public health system, OR
- •a laboratory of a recognized national or multinational influenza surveillance scheme.
- •Onset of illness no more than 40 hours before enrollment in the trial.
- •Note: Time of onset of illness is defined as either the earlier of:
- •the time when the temperature was first measured as elevated, OR
- •the time when the subject experienced the presence of at least one respiratory symptom AND the presence of at least one constitutional symptom.
- •Willing and able to provide written informed consent (including assent by legal guardian if under 18 years of age) and comply with the requirements of the protocol, including completion of the patient diary.
排除标准
- •Severity of illness requiring or anticipated to require in-hospital care.
- •Moderate or severe persistent asthma.
- •Cystic fibrosis in children.
- •Stage III or IV (severe or very severe) chronic obstructive pulmonary disease (COPD).
- •Class III or IV congestive heart failure (at least marked limitation of physical activity in which minimal ordinary activity results in fatigue, palpitation, dyspnea, or angina pain)
- •Immunosuppressive disorders or who are receiving immunosuppressive therapy (e.g., for organ or bone marrow transplants)
- •Untreated HIV infection or treated HIV infection with a CD4 count below 350 cells/mm3 in the last 6 months
- •Persons with sickle cell anemia or other hemoglobinopathies
- •Poorly controlled insulin-dependent diabetes mellitus (HBA1C > 8%)
- •Residents of any age of nursing homes or other long-term care institutions
- •Concurrent infection at the screening examination that requires systemic antimicrobial therapy.
- •Females of childbearing potential who are either pregnant, breast-feeding or are sexually active without the use of birth control. Female subjects of child-bearing potential that are sexually active must have a negative baseline pregnancy test and must agree to continue an acceptable method of birth control for the duration of the study and for 1 month post- treatment. A double barrier method, oral birth control pills administered for at least 2 monthly cycles prior to study drug administration, an IUD, or medroxyprogesterone acetate administered intramuscularly for a minimum of one month prior to study drug administration are acceptable methods of birth control for inclusion into the study. Female subjects are considered of childbearing potential unless they are postmenopausal (absence of menstrual bleeding for 1 year - or 6 months if laboratory confirmation of hormonal status), or have had a hysterectomy, bilateral tubular ligation or bilateral oophorectomy.
- •Receipt of any dose of NTZ, oseltamivir, zanamivir, peramivir, laninamivir, baloxavir, amantadine or rimantadine within 3 days prior to screening.
- •Prior treatment with any investigational drug therapy within 30 days prior to screening.
- •Subjects with active respiratory allergies or subjects expected to require anti-allergy medications during the study period for respiratory allergies.
- •Known sensitivity to NTZ or any of the excipients comprising the NTZ tablets.
- •Subjects unable to take oral medications.
- •Presence of any pre-existing illness that, in the opinion of the Investigator, would place the subject at an unreasonably increased risk through participation in this study.
- •Subjects who, in the judgment of the Investigator, will be unlikely to comply with the requirements of this protocol.
研究组 & 干预措施
Nitazoxanide
Active Comparator
Two Nitazoxanide 300 mg tablets orally twice daily (b.i.d.) for 5 days
干预措施: Nitazoxanide (Drug)
Placebo
Placebo Comparator
Two Placebo tablets orally twice daily (b.i.d.) for 5 days
干预措施: Placebo (Drug)
结局指标
主要结局
Time From First Dose to Symptom Response
时间窗: Up to 21 days
Subjects used the FLU-PRO questionnaire once daily in the evening to score the severity of 32 FLU-PRO symptoms. Symptom response was deemed achieved when the rating for each of the 32 FLU-PRO symptoms was ≤ its assigned threshold for 2 consecutive daily diary periods without use of symptom relief medication. The symptom response thresholds were developed by applying an algorithm to blinded symptoms data to select the set of 32 symptom thresholds most closely associated with patient-reported usual health.
次要结局
- Time From First Dose to Ability to Perform All Normal Activities(Up to 21 days)
- Number of Subjects Experiencing One or More Complications of Influenza(Up to 21 days)
- Time to Symptom Response Excluding the FLU-PRO Gastrointestinal and Eye Domains(Up to 21 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Acute Uncomplicated InfluenzaInfluenzaNCT02612922Romark Laboratories L.C.325
尚未招募
3 期
Trial to Evaluate Nitazoxanide for Treatment of Mild COVID-19 in Subjects Not at High Risk of Severe IllnessCOVID-19NCT05157269Romark Laboratories L.C.600
尚未招募
3 期
Trial to Evaluate Nitazoxanide for Treatment of Mild or Moderate COVID-19 in Subjects at High Risk of Severe IllnessCOVID-19NCT05157243Romark Laboratories L.C.2,000
终止
3 期
Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus InfectionEnterovirusRhinovirusNCT04489381Romark Laboratories L.C.214
已完成
3 期
Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus InfectionEnterovirusRhinovirusNCT03605862Romark Laboratories L.C.1,756